KPV

KPV is one of the smallest active peptide fragments studied in the research community — just three amino acids (lysine-proline-valine). Despite its simplicity, it recapitulates the core anti-inflammatory and wound healing activity of its parent molecule, alpha-MSH, by activating MC1R (melanocortin-1 receptor) in inflammatory cells and epithelial tissue. A distinguishing characteristic is oral bioavailability: unlike most peptides, KPV's small size and resistance to gastric degradation allow it to survive the digestive process and reach intestinal tissue intact — making oral administration viable and specifically appropriate for gut-targeted applications. KPV's primary research interest lies in inflammatory bowel disease contexts. Studies have demonstrated anti-inflammatory activity in murine colitis models, reducing pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6) and improving colonic tissue integrity. The compound has also shown antimicrobial activity against Staphylococcus aureus and Candida albicans, adding a second dimension of gut protection.

Intestinal anti-inflammatory activity is KPV's best-documented and most specific benefit. MC1R activation in intestinal epithelial cells and immune cells suppresses NF-κB-mediated inflammatory signaling — the central driver of IBD pathology. In colitis mouse models, KPV treatment reduces histological damage scores, decreases inflammatory cytokine levels, and improves barrier function. Oral bioavailability for gut applications is KPV's practical advantage over BPC-157 for the intestinal inflammation use case. While BPC-157 also shows GI benefits, KPV's targeted MC1R mechanism and oral stability make it specifically well-suited for local intestinal action without requiring injection. Antimicrobial activity against common gut pathogens (S. aureus and Candida) adds a protective dimension relevant to gut microbiome balance and prevention of opportunistic infections in compromised intestinal barriers. Wound healing at the cellular level — stimulating keratinocyte and fibroblast migration — has been demonstrated in tissue culture studies, with potential topical and injectable wound healing applications.

KPV has an excellent safety profile in animal studies with no documented significant adverse effects. Its small size, natural origin (fragment of endogenous alpha-MSH), and well-characterized MC1R mechanism predict a low toxicity profile. GI discomfort at high oral doses has been reported anecdotally — not unexpected given any high-dose oral compound's potential for GI effects. The absence of controlled human trial data means the true side effect profile in humans is not formally characterized, though the mechanistic and animal safety data are reassuring.

Oral dosing: 500 mcg to 2 mg/day, taken with meals for IBD or gut inflammation applications. The oral route is preferred for gut-targeted effects given KPV's demonstrated intestinal bioavailability. SubQ injection: 100–200 mcg once or twice daily for systemic anti-inflammatory effects or wound healing applications. Topical: Some practitioners use KPV in topical formulations for skin conditions such as psoriasis or inflammatory dermatoses, typically at 0.1–1% concentration. Cycle length: Unlike hormonal compounds, KPV doesn't require cycling for receptor tolerance or hormonal reasons. Continuous use for active IBD management is theoretically reasonable, though long-term data is absent.

KPV is a research chemical with no regulatory approval for human use. As a natural fragment of endogenous alpha-MSH, it may face fewer regulatory hurdles than novel synthetic compounds if it progresses to clinical development. Not a controlled substance. WADA does not prohibit it.

KPV + BPC-157: A comprehensive gut healing stack. BPC-157 addresses mucosal healing, angiogenesis, and ulcer protection through growth factor and nitric oxide pathways; KPV adds MC1R-mediated anti-inflammatory activity and antimicrobial protection. Together they address gut pathology from multiple mechanistic angles. KPV oral + Selank: Combining gut anti-inflammatory (KPV) with anxiolytic peptide (Selank) is used by some practitioners focused on the gut-brain axis and stress-related GI conditions.

KPV — Common Questions